Investigational drug · Phase 2
CR6086
Also called: vorbipiprant
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "CR6086"
First trial start
2021
Nov 23, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CR6086", any sponsor or status.
Conditions studied
As listed on its trial records.
- Refractory Metastatic Colorectal Cancer
- Solid Tumor
- Metastatic Microsatellite-stable Colorectal Cancer
- Mismatch Repair Protein Proficient
- Metastatic GI Cancers
- Gastric Cancer
Approved drugs for the same conditions: Colorectal cancer · Stomach and esophageal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CR6086" as an intervention, largest first.
- A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid ArthritisPivotal-lookingCompleted
Rottapharm BiotechIndustry
NCT03163966 · 248 participants · Start Oct 5, 2017 · Primary completion Jan 8, 2019
Drug: CR6086; Methotrexate and 1 more · For: Rheumatoid Arthritis, DMARD-naive and Early Disease Patients
Sites: Prague, Czechia
- Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI CancersActive, not recruiting
Rottapharm BiotechIndustry
NCT05205330 · 107 participants (planned) · Start Nov 23, 2021 · Primary completion Dec 2026
Drug: CR6086; AGEN2034 · For: Refractory Metastatic Colorectal Cancer; Solid Tumor; Metastatic Microsatellite-stable Colorectal Cancer and 3 more
Sites: Milan, Italy; Padova, Italy; Pisa, Italy
Newest research
PubMed records naming it or its code names, newest first.
- The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial.
Pietrantonio F, Morano F, Niger M, et al. · Clin Cancer Res 2025
- Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug.
Caselli G, Bonazzi A, Lanza M, et al. · Arthritis Res Ther 2018
Also in development for Refractory Metastatic Colorectal Cancer
- SuvemcitugPhase 31 trial
Jiangsu Simcere Pharmaceutical Co., Ltd. · Refractory Metastatic Colorectal Cancer
- BalstilimabAGEN2034Phase 23 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.